Hepatitis C medications approved in March this year have already topped the list of Australia's most expensive drugs, costing the taxpayer $1 billion. The latest figures have outlined 10 most prescribed and most expensive drugs on the Pharmaceutical Benefits Scheme (PBS) in the past year.
05 December 2016 | ABC Online
A new WHO report provides insight into how countries in the WHO European Region can improve access and reduce medicine prices through strategic and well-planned procurement processes. The report examines the effect of different public procurement practices on supply security and prices for pharmaceuticals. It also addresses collaboration within and across countries to improve availability of affordable medicines for patients in the Region.
02 December 2016 | World Health Organization
Patients infected by hepatitis C virus (HCV) in Canada have limited access to direct-acting antiviral (DAA) agents, according to a new study. For example, 85% to 92% of the provinces and territories in Canada restrict access to these medications to persons with moderate fibrosis.
29 November 2016 | Medical Economics
With the opioid epidemic steamrolling through Appalachia, the new face of hepatitis C is increasingly young, white, and rural. In Kentucky, a state beset by hepatitis C rates seven times the national average, Harvoni and other new hepatitis C drugs remain largely out of reach.
14 November 2016 | STAT
To avoid the cost and uncertainty of challenging behemoth drug companies in the American market, Trek plans to focus on middle-income countries where new hepatitis C drugs have been slow to roll out, such as nations in eastern and central Europe. If they are successful at finding a new balancing point of profit and access -- a true "if" -- they hope their example could inspire companies working on other diseases to experiment with similar pricing models.
08 November 2016 | Washington Post
Frustrated by the high price of antiviral drugs, thousands of patients from London to Moscow to Sydney are turning to a new wave of online "buyers clubs" to get cheap generic medicines to cure hepatitis C and protect against HIV infection.
07 November 2016 | Reuters
Preliminary estimates, based on data obtained from CMS by the Associated Press, suggest that 2015 spending on the new hepatitis C drugs was $9.2 billion or roughly double the 2014 levels. This level of spending projects to about 100,000 new individual users, allowing for some duplication of people who continued the treatment they started in 2014.
04 November 2016 | Health Affairs (blog)
Gilead Sciences Inc. on Tuesday said sales of hepatitis C drugs Harvoni and Sovaldi missed expectations and slumped in the third-quarter, as the biopharmaceutical company faces challenges from rival drugs and pricing pressures.
02 November 2016 | MarketWatch
Over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.
27 October 2016 | World Health Organization
Georgia, a country nestled against the Black Sea between Turkey and Russia with a population of 3.7 million, has since taken on a public health effort to help reduce its prevalence of hepatitis C (HCV for short) by 90% by 2020.
24 October 2016 | Business Insider